(loo-li-kon-a-zole) ,


(trade name)


Therapeutic: antifungals
Pharmacologic: azoles
Pregnancy Category: C


Topical treatment of interdigital tinea pedis, tinea cruris and tinea corporis.


Inhibits an enzyme necessary for ergosterol synthesis, required for fungal cell membranes.
Antifungal action.

Therapeutic effects

Resolution of dermal fungal infection.
Active against Trichyphyton rubrum and Epidermpophyton floccosum.


Absorption: Small amounts are systemically absorbed.
Distribution: Unknown.
Protein Binding: >99%
Metabolism and Excretion: Unknown.
Half-life: unk

Time/action profile (improvement/resolution of infection)

topunk3–4 wk†unknown
†Following initiation of treatment.


Contraindicated in: None noted;
Use Cautiously in: Obstetric: Use in pregnancy only if potential benefit justifies any fetal risks; Lactation: Use cautiously in breast feeding women. Pediatric: Safe and effective use in children <18 yr not established.

Adverse Reactions/Side Effects


  • application site reactions


Drug-Drug interaction

May inhibit the activity of the CYP3A4 and CYP2C19 enzymes.


Topical (Adults) Interdigital tinea pedisApply to affected and surrounding areas once daily for two weeks; Tinea cruris and tinea corporisApply to affected and surrounding areas once daily for one week.


Topical cream: 1%

Nursing implications

Nursing assessment

  • Inspect involved areas of skin and mucous membranes before and frequently during therapy. Increased skin irritation may indicate need to discontinue medication.

Potential Nursing Diagnoses

Risk for impaired skin integrity (Indications)
Risk for infection (Indications)


  • Consult health care professional for proper cleansing technique before applying medication.
  • Topical: For Interdigital tinea pedis: Apply thin layer to cover affected area and approximately 1 inch of immediate surrounding area completely daily for 2 wk.
    • For Tinea Cruris or Tinea Corporis: Apply thin layer to affected area and approximately 1 inch of immediate surrounding area daily for 1 wk.
    • Avoid the use of occlusive wrappings or dressings unless directed by health care professional. Wash hands after application.

Patient/Family Teaching

  • Instruct patient to apply medication as directed for full course of therapy, even if feeling better. Emphasize the importance of avoiding the eyes and vagina.
  • Patients with athlete’s foot should be taught to wear well-fitting, ventilated shoes, to wash affected areas thoroughly, and to change shoes and socks at least once a day.
  • Advise patient to report increased skin irritation or lack of response to therapy to health care professional.
  • Instruct patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and consult health care professional before taking any new medications.
  • Advise female patient to notify health care professional if pregnancy is planned or suspected or if breastfeeding.

Evaluation/Desired Outcomes

  • Decrease in skin irritation and resolution of infection.
References in periodicals archive ?
For tinea pedis, naftifine 2% and luliconazole 1% are new agents, both administered for relatively short courses, that may foster greater adherence
A good option in diabetic patients is luliconazole (Luzu), which is active against Trichophyton rubrum--the most common causative organism--and has the advantage of simplicity: The regimen is once-daily treatment for 2 weeks, much shorter than for many other topical antifungals, Dr.
Luliconazole is an azole drug, meaning it is broad spectrum and kills dermatophytes, yeast, and molds.
Luliconazole (Luzu), an azole anti-fungal, is a cream used for the treatment of tinea pedis, tinea cruris, and tinea corporis.
Luliconazole (Dermatophytic Onychomycosis) - Forecast and Market Analysis to 2022
M2 PHARMA-October 19, 2011-Topica gets USD27m financing to advance luliconazole studies(C)2011 M2 COMMUNICATIONS
Luliconazole is one of the most potent and broad- spectrum topical antifungal agents in development and will be advancing to Phase 3 clinical development in the U.
Pariser, who shared data about luliconazole and a new formulation of naftifine as topical treatments for tinea infections at the Skin Disease Education Foundation s annual Las Vegas dermatology seminar.
A 1% topical luliconazole cream yielded complete clearance in more than 20% of patients with tinea cruris and patients with tinea pedis, compared with less than 10% of placebo patients in a pair of randomized, multicenter double-blind studies.